article_metadata: Liang Wen Xiuwen Zou Yiwen Chen Xueli Bai Tingbo Liang
article_metadata: 10.3389/fimmu.2020.02076
article_metadata: Front Immunol
article_metadata: 2020 Aug 21;11:2076.
article_metadata: pd-1 inhibitor sintilimab autoimmune diabetes hepatocellular carcinoma immune related adverse event plasma glucose
article_metadata: CC BY
article_metadata: https://pubmed.ncbi.nlm.nih.gov/32973816/
article_metadata: Antibodies, Monoclonal, Humanized / adverse effects Antineoplastic Agents, Immunological / adverse effects Carcinoma, Hepatocellular / drug therapy Diabetes Mellitus, Type 1 / diagnosis Immune Checkpoint Inhibitors / adverse effects Immunotherapy / methods Liver Neoplasms / drug therapy
article_metadata: Antibodies, Monoclonal, Humanized / adverse effects Antineoplastic Agents, Immunological / adverse effects Carcinoma, Hepatocellular / drug therapy Diabetes Mellitus, Type 1 / diagnosis Immune Checkpoint Inhibitors / adverse effects Immunotherapy / methods Liver Neoplasms / drug therapy Case Reports Research Support, Non-U.S. Gov't Antibodies, Monoclonal, Humanized / therapeutic use Antineoplastic Agents, Immunological / therapeutic use Autoantibodies / blood China Diabetes Mellitus, Type 1 / etiology Glucose / metabolism Humans Immune Checkpoint Inhibitors / therapeutic use Insulin / administration & dosage Male Middle Aged Programmed Cell Death 1 Receptor / immunology Antibodies, Monoclonal, Humanized Antineoplastic Agents, Immunological Autoantibodies Immune Checkpoint Inhibitors Insulin PDCD1 protein, human Programmed Cell Death 1 Receptor sintilimab Glucose
article_metadata: PMC7472830
article_metadata: 32973816
article_metadata: Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression
article_metadata: 2020